Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Slideshows|April 13, 2018
Treating Adolescent Depression With Psychotherapy: A Quiz
Author(s)Sanno E. Zack, PhD
Empirically supported psychotherapeutic treatments have been shown to reduce symptoms of depression and build problem-solving skills in adolescents. Three of those treatments are discussed in this 10-question quiz.
Advertisement
Advertisement
Related to this article
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
Presenting Our November 2026 Theme: Emergency Psychiatry
3
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5